Menopausal Hot Flashes Market: Snapshot
A substantial rise in occurrence of vasomotor symptoms or hot flashes and night sweats resulting from menopause is the single most important growth driver in the global menopausal hot flashes market. Another factor creating demand in the market is the favorable initiatives undertaken by governments and private healthcare institutes in raising awareness about women’s health. Fettering the positive effect of such growth drivers in the market is the imminent patent expirations of popular drugs and products paving the way for cheaper generic drugs in the near future. This is forecasted to deal a blow to the bottom lines of most of the prominent players in the global market for menopausal hot flashes products.
As a result, the global market for menopausal hot flashes is predicted to exhibit a sluggish CAGR of 3.7% between 2015 and 2023 to reach a value of US$5,284.1 mn by 2023 from US$ 3,774.5 mn in 2014.
The global menopausal hot flashes market is somewhat fragmented with the topmost eight vendors accounting for about half the market share. Among them, the top two – Pfizer, Inc. and Novartis AG – hold almost 30% of the market share. Going forward too, they are expected to maintain their stronghold in the market. Pfizer, for example, dominates the crucial North America market which is the leading buyer of menopausal hot flashes treatment products.
Health Hazards Posed by Hormone Replacement Therapies to Damp their Demand
Hormone replacement therapies, entailing hormones such as progestin and estrogen, for a long time remained the most preferred method for tackling menopausal hot flashes. In fact, it accounted for a staggering 95.0% share in the market up until a while back. Recent studies, however, have revealed that the much practiced treatment can pose danger to women’s health by upping chances of cancer and cardiovascular diseases in them. This has negatively impacted demand for hormone-based therapies for menopausal hot flashes and hence in the years ahead its demand is expected to increase at a lackluster 3.2% CAGR through 2023.
Growth in demand for non-hormonal therapies for menopausal hot flashes, on the contrary, is slated to far outstrip that of hormone replacement therapies in the near future. It is expected to exhibit a robust CAGR of 13.8% from 2015 to 2023. However, even with the cracking pace of demand growth, non-hormonal replacement therapies will not be able to beat the hormonal replacement therapies in the terms of market share anytime soon. This is due to the solid global market penetration of hormonal replacement therapies and lack of proper alternatives in non-hormonal replacement therapies available in the market.
Rising Knowledge of Vasomotor Symptoms to Drive Asia Pacific Market
Currently, the North America market outshines all other regional segments because of the high instances of menopausal vasomotor symptoms in women in the continent. Its share in the global menopausal hot flashes is about a substantial 66.0%. Europe trails North America with a much lesser market share. In the upcoming years, the two continents are predicted to retain their leading positions due the strong awareness about menopausal hot flashes among women and the fast growing population of women aged between 40 to 65 years in the regions.
Exhibiting a healthy CAGR of 6.7% from 2015 to 2023, Asia Pacific will likely outshine all other regions vis-à-vis growth. The increasing awareness about menopause-related health issues among women, increasing disposable incomes, and a sizeable proportion of women between 35 and 65 years of age will fuel a significant uptick in demand in the region.
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Menopausal Hot Flashes Market Snapshot
2.2. Global Menopausal Hot Flashes Market Share, by Geography, 2014 & 2023 (Value %)
2.3. Global Menopausal Hot Flashes Market Revenue, by Geography, 2014 (US$ Mn)
2.4. Global Menopausal Hot Flashes Market, by Therapy, 2014 (US$ Mn)
3. Menopausal Hot Flashes Market - Industry Analysis
3.2. Market Dynamics
184.108.40.206. Rise in menopausal vasomotor symptoms across the globe
220.127.116.11. Approval of new treatment options
18.104.22.168. Growing women health awareness
22.214.171.124. Risk of breast cancer with HRT treatment
126.96.36.199. Growing demand for alternative therapies
188.8.131.52. Emerging economies to offer sustained growth opportunities
3.3. Market Attractiveness Analysis, by Geography, 2014
3.4. Competitive Landscape, Market Share Analysis, by Key Players, 2014 (Value %)
4. Market Segmentation – By Therapy
4.2. Global Menopausal Hot Flashes Revenue, by Therapy, 2013–2023 (US$ Mn)
4.3. Global Menopausal Hot Flashes Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4. Global Hormonal Therapy Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4.1. Global Estrogen Market Revenue, 2013–2023, (US$ Mn)
184.108.40.206. Global Premarin Flashes Market Revenue, 2013–2023, (US$ Mn)
220.127.116.11. Global Vivelle-Dot Market Revenue, 2013–2023, (US$ Mn)
4.4.2. Global Progestin Market Revenue, 2013–2023, (US$ Mn)
18.104.22.168. Global Prometrium Market Revenue, 2013–2023, (US$ Mn)
4.4.3. Global Combination Therapy Market Revenue, 2013–2023, (US$ Mn)
22.214.171.124. Global Duavee Market Revenue, 2013–2023, (US$ Mn)
126.96.36.199. Global Prempro Market Revenue, 2013–2023, (US$ Mn)
4.5. Global Non-hormonal Market Revenue, 2013–2023, (US$ Mn)
4.5.1. Global Brisdelle Market Revenue, 2013–2023, (US$ Mn)
5. Pipeline Analysis
5.1. Phase I and II Drugs, Tabular Representation
5.2. Menopausal Hot Flashes Phase III Drugs Market Revenue, 2017 - 2023 (USD Million)
6. Market Segmentation – By Geography
6.1. Global Menopausal Hot Flashes Market Revenue, by Geography, 2013–2023
6.1.1. North America Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.2. Europe Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.3. Asia Pacific Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.4. Rest of the World Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
8. Company Profiles
8.1. Allergan plc
8.2. Bayer AG
8.3. Hisamitsu Pharmaceutical Co., Inc.
8.4. Merck & Co., Inc.
8.5. Novartis International AG
8.6. Novo Nordisk
8.7. Pfizer, Inc.
8.8. Teva Pharmaceutical Industries Ltd.
This report on the menopausal hot flashes market studies the current and future prospects of the treatment across the globe. Hot flashes are common symptoms experience by women in menopause transition. Hot flashes are defined as ephemeral, recurring periods of heat sensation and redness, often associated with sweat and are experienced by about 75% of women in the U.S and Europe at some point before or during the menopause period. These tend to decrease in severity and frequency over a few months to a few years, but sometimes persist into old age.
The menopausal hot flashes market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global menopausal hot flashes drugs market with respect to the segments based on the type of therapy, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global menopausal hot flashes market.
Based on therapy type, the menopausal hot flashes market has been segmented into two major categories: hormonal and non-hormonal treatment. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global menopausal drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, Rest of Europe), Asia Pacific (Japan, Australia, India, China, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global menopausal hot flashes market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co. Inc., Novartis International AG, Novo Nordisk, Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.
The global menopausal hot flashes market is segmented as follows:
Global Menopausal Hot Flashes Market, by Therapy Type
- Combination Therapy
Global Menopausal Hot Flashes Market, Pipeline Analysis
- Phase I and II Drugs
- Phase III Drugs
Global Menopausal Hot Flashes Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Middle East and Africa